Capricor Therapeutics CAPR
NASDAQ CAPR
$8.94 -0.53 (-5.60%)
At close: Oct 1, 2026 · 4:00 PM EDT

Capricor Therapeutics (CAPR) Cash from Financing Activities (2010 - 2026)

Updated

Capricor Therapeutics' Cash from Financing Activities was -$4.24 million in Q2 2026, compared with $19,580 a year earlier.

Analysis

Capricor Therapeutics (CAPR) Cash from Financing Activities (2010 - 2026) Analysis & Trends

On a trailing twelve-month basis, Capricor Therapeutics' Cash from Financing Activities was $246.05 million through Jun 30, 2026, up 65.7% year-over-year; for FY2025, it came in at $248.89 million, up 62.9% from FY2024.

  • Cash from Financing Activities has now increased for three consecutive years, with a five-year compound annual growth rate of 49.5% (FY2020 to FY2025).
  • In earlier years, Cash from Financing Activities was $152.77 million in FY2024 (+497.2%), $25.58 million in FY2023 (+424.8%), $4.87 million in FY2022 (-75.9%) and $20.23 million in FY2021 (-39.4%).
  • The Q2 2026 figure marks the lowest quarterly Cash from Financing Activities in data going back to Q3 2010.
  • Compared with a year earlier, Cash from Financing Activities was higher in two of the last five quarters, with growth averaging 32.0%.
  • The best year-over-year quarter for Cash from Financing Activities over five years was Q4 2023 (growth of 685.4%); the worst was Q3 2025 (a decline of 100.0%).
  • Per Business Quant data, CAPR's Cash from Financing Activities in the three quarters before Q2 2026 was $1.47 million (Q1 2026), $248.82 million (Q4 2025) and $6,950 (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -8.78 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -5.05 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 1.76 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -2.02 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -47.00 Mn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -1.48 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 2.34 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -3.66 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -426.70 Mn
10 Capricor Therapeutics 550.29 Mn 550.29 Mn - -4.24 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -4.24 Mn
Mar 31, 2026 1.47 Mn
Dec 31, 2025 248.82 Mn
Sep 30, 2025 6,950.00
Jun 30, 2025 19,580.00
Mar 31, 2025 50,354.00
Dec 31, 2024 81.09 Mn
Sep 30, 2024 67.33 Mn
Jun 30, 2024 2.07 Mn
Mar 31, 2024 2.29 Mn
Dec 31, 2023 23.17 Mn
Sep 30, 2023 221,081.00
Jun 30, 2023 2.19 Mn
Mar 31, 2023 3,895.00
Dec 31, 2022 2.95 Mn
Sep 30, 2022 1.88 Mn
Jun 30, 2022 15,006.00
Mar 31, 2022 27,465.00
Dec 31, 2021 42,370.00
Sep 30, 2021 6.57 Mn
API Access

Capricor Therapeutics Cash from Financing Activities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-financing-activities&ticker=CAPR&period=max&api_key=YOUR_API_KEY